The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AADI BIOSCIENCE INC | COM | 00032Q104 | 830,601 | 64,739 | SH | OTR | 1 | 0 | 64,739 | 0 | ||
| ALPINE IMMUNE SCIENCES INC | COM | 02083G100 | 22,977,372 | 3,126,173 | SH | OTR | 1 | 0 | 3,126,173 | 0 | ||
| BELLUS HEALTH INC NEW | COM NEW | 07987C204 | 8,991,858 | 1,093,900 | SH | OTR | 1 | 0 | 1,093,900 | 0 | ||
| CABALETTA BIO INC | COM | 12674W109 | 26,140,278 | 2,825,976 | SH | OTR | 1 | 0 | 2,825,976 | 0 | ||
| CYMABAY THERAPEUTICS INC | COM | 23257D103 | 10,367,414 | 1,653,495 | SH | OTR | 1 | 0 | 1,653,495 | 0 | ||
| KINNATE BIOPHARMA INC | COM | 49705R105 | 12,190,344 | 1,998,417 | SH | OTR | 1 | 0 | 1,998,417 | 0 | ||
| MERUS N V | COM | N5749R100 | 13,220,523 | 854,591 | SH | OTR | 1 | 0 | 854,591 | 0 | ||
| NEOLEUKIN THERAPEUTICS INC | COM | 64049K104 | 1,166,187 | 2,291,133 | SH | OTR | 1 | 0 | 2,291,133 | 0 | ||
| PARDES BIOSCIENCES INC | COM | 69945Q105 | 5,075,242 | 3,003,102 | SH | OTR | 1 | 0 | 3,003,102 | 0 | ||
| PASSAGE BIO INC | COM | 702712100 | 4,631,165 | 3,355,917 | SH | OTR | 1 | 0 | 3,355,917 | 0 | ||
| PHARVARIS N V | COM | N69605108 | 284,906 | 25,325 | SH | OTR | 1 | 0 | 25,325 | 0 | ||
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 5,853,728 | 5,628,585 | SH | OTR | 1 | 0 | 5,628,585 | 0 | ||
| THESEUS PHARMACEUTICALS INC | COM | 88369M101 | 3,905,107 | 784,158 | SH | OTR | 1 | 0 | 784,158 | 0 | ||